KMDA Kamada Ltd.

7.4
+0.12  (+2%)
Previous Close 7.28
Open 7.34
Price To Book 2.31
Market Cap 299,792,337
Shares 40,512,478
Volume 28,796
Short Ratio
Av. Daily Volume 54,157
Stock charts supplied by TradingView

NewsSee all news

  1. Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

    REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize

  2. Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019

    Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.As a Reminder, Kamada's

  3. Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13

    REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and

  4. Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

    REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a

  5. Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

    Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due YE 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
KamRAB
Prophylaxis of rabies disease
Phase 3 (Europe) trial planned for 2H 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 interim data due 2020.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)

Latest News

  1. Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

    REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize

  2. Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019

    Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.As a Reminder, Kamada's

  3. Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13

    REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and

  4. Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

    REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a

  5. Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

    Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada